Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.

Boyd A, Moh R, Maylin S, Abdou Chekaraou M, Mahjoub N, Gabillard D, Anglaret X, Eholié SP, Delaugerre C, Danel C, Zoulim F, Lacombe K; ANRS 12240 VarBVA study.

J Viral Hepat. 2018 Oct;25(10):1121-1131. doi: 10.1111/jvh.12914. Epub 2018 May 9.

PMID:
29660214
2.

Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.

Boyd A, Maylin S, Moh R, Mahjoub N, Gabillard D, Eholié SP, Danel C, Anglaret X, Zoulim F, Girard PM, Delaugerre C, Lacombefor K; ANRS 12240 VarBVA study.

J Gastroenterol Hepatol. 2016 Mar;31(3):634-44. doi: 10.1111/jgh.13156.

PMID:
26313291
3.

Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.

Boyd A, Gozlan J, Miailhes P, Lascoux-Combe C, Cam MS, Rougier H, Zoulim F, Girard PM, Lacombe K.

AIDS. 2015 Sep 24;29(15):1963-73. doi: 10.1097/QAD.0000000000000795.

PMID:
26153669
4.

Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy.

Hung CH, Chen CH, Lu SN, Wang JH, Hu TH, Huang CM, Tsai MC, Lee CM.

Antiviral Res. 2012 Jan;93(1):55-63. doi: 10.1016/j.antiviral.2011.10.018. Epub 2011 Oct 28.

PMID:
22061616
5.

Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.

Boyd A, Piroth L, Maylin S, Maynard-Muet M, Lebossé F, Bouix C, Lascoux-Combe C, Mahjoub N, Girard PM, Delaugerre C, Carrat F, Lacombe K, Miailhes P.

J Viral Hepat. 2016 Dec;23(12):1017-1026. doi: 10.1111/jvh.12581. Epub 2016 Aug 3.

PMID:
27486094
6.

Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.

Belyhun Y, Liebert UG, Maier M.

PLoS One. 2018 Feb 6;13(2):e0191970. doi: 10.1371/journal.pone.0191970. eCollection 2018.

7.

Correlation between the promoter basal core and precore mutations and HBsAg quantification in French blood donors infected with hepatitis B virus.

Pivert A, Servant-Delmas A, Lunel-Fabiani F, Le Guillou-Guillemette H, Laperche S, Ducancelle A.

J Med Virol. 2015 Mar;87(3):529-35. doi: 10.1002/jmv.24064. Epub 2014 Aug 29.

PMID:
25170961
8.

HBsAg, HBeAg and HBV DNA level changes and precore/basal core promoter mutations in the natural history of chronic hepatitis B in Indonesian patients.

Turyadi, Thedja MD, Ie SI, Harahap AR, El-Khobar KE, Roni M, Muljono DH.

Hepatol Int. 2013 Oct;7(4):969-80. doi: 10.1007/s12072-013-9438-z. Epub 2013 May 23.

PMID:
26202027
9.
10.

Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.

Strassl R, Reiberger T, Honsig C, Payer BA, Mandorfer M, Grabmeier-Pfistershammer K, Rieger A, Kundi M, Grundtner P, Peck-Radosavljevic M, Popow-Kraupp T.

J Viral Hepat. 2014 Jul;21(7):508-16. doi: 10.1111/jvh.12175. Epub 2013 Sep 24.

PMID:
24112778
11.

Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients.

Yan CH, Zhao CY, Ding H, Peng YQ, Jin PY, Yan L, Zhuang H, Li T.

Antiviral Res. 2012 Nov;96(2):108-14. doi: 10.1016/j.antiviral.2012.08.009. Epub 2012 Aug 31.

PMID:
22960603
12.

Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients.

Hu HH, Liu J, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, Quan Y, Xia NS, Chen CJ, Chen PJ, Yang HI.

Clin Gastroenterol Hepatol. 2018 May 9. pii: S1542-3565(18)30472-5. doi: 10.1016/j.cgh.2018.04.064. [Epub ahead of print]

PMID:
29753083
13.

Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B.

Yang HI, Hung HL, Lee MH, Liu J, Jen CL, Su J, Wang LY, Lu SN, You SL, Iloeje UH, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer–HBV (REVEAL-HBV) Study Group.

Clin Gastroenterol Hepatol. 2012 May;10(5):527-34.e1-2. doi: 10.1016/j.cgh.2011.12.019. Epub 2011 Dec 16.

PMID:
22178461
14.

Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.

Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, Pas SD, Hansen BE, Janssen HL.

Hepatology. 2012 Jul;56(1):67-75. doi: 10.1002/hep.25636. Epub 2012 Apr 25.

PMID:
22307831
15.

The nucleotide changes within HBV core promoter/precore during the first 12weeks of nucleos(t)ide treatment might be associated with a better virological response.

Peng Y, Li Y, Hou J, Sun J, Su M, Li Y, Xiang K, Yan L, Zhuang H, Li T.

Infect Genet Evol. 2017 Apr;49:116-121. doi: 10.1016/j.meegid.2017.01.009. Epub 2017 Jan 12.

PMID:
28088502
16.

[Characterization of basal core promoter/precore gene mutations in chronically infected patients with hepatitis B virus genotype D in Mersin Province, Turkey].

Tezcan S, Ülger M, Üçbilek E, Aslan G, Serin MS, Sezgin O, Delialioğlu N, Altıntaş E, Helvacı İ, Emekdaş G.

Mikrobiyol Bul. 2015 Jul;49(3):377-92. Turkish.

17.

Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection.

Zhong YW, Di FL, Liu C, Zhang XC, Bi JF, Li YL, Wu SQ, Dong H, Liu LM, He J, Shi YM, Zhang HF, Zhang M.

Clin Microbiol Infect. 2016 Apr;22(4):379.e1-379.e8. doi: 10.1016/j.cmi.2015.10.033. Epub 2015 Nov 11.

18.

Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa.

Boyd A, Moh R, Maylin S, Abdou Chekaraou M, Mahjoub N, Gabillard D, Anglaret X, Eholié SP, Danel C, Delaugerre C, Zoulim F, Lacombe K; ANRS 12240 VarBVA study.

Liver Int. 2018 Sep 26. doi: 10.1111/liv.13975. [Epub ahead of print]

PMID:
30257068
19.

Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients.

Boyd A, Lacombe K, Lavocat F, Miailhes P, Lascoux-Combe C, Girard PM, Zoulim F.

Antiviral Res. 2018 Jan;149:174-178. doi: 10.1016/j.antiviral.2017.11.014. Epub 2017 Nov 21.

PMID:
29169914
20.

Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B.

Lin CL, Liao LY, Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS.

J Gastroenterol. 2002;37(4):283-7.

PMID:
11993512

Supplemental Content

Support Center